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Wnt signaling through both canonical and noncanonical pathways
plays a core role in development. Dysregulation of these pathways
often causes cancer development and progression. Although the
pathways independently contribute to the core processes, a regula-
tory molecule that commonly activates both of them has not yet
been reported. Here, we describe a long noncoding RNA (lncRNA),
HERES, that epigenetically regulates both canonical and noncanonical
Wnt signaling pathways in esophageal squamous cell carcinoma
(ESCC). For this study, we performed RNA-seq analysis on Korean
ESCC patients and validated these results on a larger ESCC cohort to
identify lncRNAs commonly dysregulated in ESCCs. Six of the dys-
regulated lncRNAs were significantly associated with the clinical
outcomes of ESCC patients and defined 4 ESCC subclasses with
different prognoses. HERES reduction repressed cell proliferation,
migration, invasion, and colony formation in ESCC cell lines and
tumor growth in xenograft models. HERES appears to be a transacting
factor that regulates CACNA2D3, SFRP2, and CXXC4 simultaneously
to activate Wnt signaling pathways through an interaction with
EZH2 via its G-quadruple structure-like motif. Our results suggest
that HERES holds substantial potential as a therapeutic target for
ESCC and probably other cancers caused by defects inWnt signaling
pathways.
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The Wnt signaling pathway is a well-known, evolutionarilyconserved pathway that plays important roles in embryonic
development; it has also been widely implicated in numerous
tumor malignancies (1–4). Wnt signaling can activate both β-catenin–
dependent (canonical) and -independent (noncanonical) signal
transduction cascades (3, 4). Canonical Wnt signaling results in
translocation of the transcriptional activator β-catenin into the
nucleus during embryonic development and cell differentiation
(5). Constitutive activation of this pathway by various causes
leads to developmental diseases and carcinogenesis (6). In contrast,
noncanonical Wnt pathways are known to be transduced by Wnt
polarity, Wnt-Ca2+, and Wnt-atypical protein kinase signaling,
independent of β-catenin transcriptional activity (7). These path-
ways have also been reported to be independently involved in
cancer development as well as embryonic development. In par-
ticular, abnormal intracellular levels of the second messenger
Ca2+ promote the Wnt signaling pathway, which in turn promotes
the development and progression of many types of cancers (8).
Controlling Wnt signaling may be a useful strategy for curing
cancers caused by aberrations in such signaling. The inhibition of
either aberrant canonical or noncanonical Wnt signaling, how-
ever, has been shown to decrease progression in only a subset of
cancers in a context-dependent manner (9). Because aberrations
in Wnt signaling pathways result from various causes, such
as mutations in different Wnt signaling-related genes, ligand
overexpression, and dysregulation of regulators, targeting only
the canonical Wnt signaling pathway might not be a universal ther-
apeutic approach for cancers. Thus, the simultaneous inhibition
of aberrant canonical and noncanonical Wnt signaling pathways
could also benefit cancer therapy.
Esophageal squamous cell carcinoma (ESCC), a major histo-
logical type of primary esophageal cancer in east Asia and other
developing countries, is associated with a very poor survival rate
that is only 5–15% at 5 y (10, 11), mainly due to delayed diagnosis,
a high rate of metastasis, and a lack of effective treatment
strategies (10–12). Moreover, the benefits of curative surgery for
advanced stages of ESCC are still unclear (11, 13), and although
cisplatin-based chemotherapy is commonly used, the effects are
inconsistent among individuals (12, 14). Despite ongoing trials
with combination therapy, efforts to identify appropriate targets
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to improve the therapy for ESCC have been largely unsuccessful
(15, 16).
Long noncoding RNAs (lncRNAs), defined as transcripts
longer than 200 nt that do not code for functional proteins (17,
18), have been proposed as regulators of critical biological pro-
cesses and cancer-related mechanisms (19–21). Because lncRNAs
can modulate multiple targets at the transcriptional and post-
transcriptional levels, lncRNAs tend to play functional roles in
more than 1 biological pathway. Moreover, mounting evidence
indicates that aberrant lncRNA expression, by modulating cancer-
related pathways, can be responsible for cancer progression (22,
23). To date, hundreds of lncRNAs have been reported to be
dysregulated in cancers and dozens of them have been known to
be associated with cancer progression. With respect to ESCC
development, the function of a few lncRNAs, including LUCAT1
and CASC9, have been investigated via a candidate-gene ap-
proach (24, 25). Recently, a Chinese group performed high-
throughput RNA sequencing (RNA-seq) on tissue from 15
paired ESCC patients and normal individuals and identified
lncRNAs dysregulated in ESCCs (26). Furthermore, they de-
scribed a lncRNA that affects cell proliferation and invasion in
ESCC cell lines but did not determine a mechanism of action.
Thus, the identification of ESCC-driving lncRNAs and an in-
vestigation of their cancer-driving mechanisms have not been
simultaneously carried out.
Through integrative analyses of ESCC-driving lncRNAs, we
found 6 lncRNAs associated with cancer progression and re-
lapse. We also determined that a lncRNA, HERES (highly
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Fig. 1. Characterization of a common set of DE lncRNAs in ESCC. (A) Venn diagram of the DE lncRNAs detected in 3 ESCC cohorts (YSH, Chinese, and
GTEx+TCGA). The pie charts (B–F) show the number of DE lncRNAs categorized according to their genomic location (B), subcellular localization (C), enhancer
overlap (D), association with DNAmethylation (E), and prognostic power (F). (G) The 4 ESCC subclasses based on the 6 prognostic marker lncRNAs in F. The top
section presents cohort information, clinical history, pathological features, and survival information from the YSH and TCGA ESCC patients. The various
categories are represented as different colors, as shown in the legend on the right. OS is overall survival. The expression patterns of the 6 prognosis-related
lncRNAs in the RNA-seq datasets are shown with a colored heatmap in the bottom section (red indicates the top 33% highly expressed lncRNAs associated
with a HHR; blue indicates the top 33% highly expressed lncRNAs associated with a LHR).
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expressed lncRNA in esophageal squamous cell carcinoma),
promoted tumor progression by regulating components of the
canonical and noncanonical Wnt signaling pathways via in-
teraction with EZH2, a subunit of polycomb repressive complex
2 (PRC2).
Results
High-Confidence Differentially Expressed (DE) lncRNAs in ESCC. To
identify a set of lncRNAs dysregulated in ESCC, RNA-seq
performed from paired cancerous and noncancerous tissues of
13 ESCC patients in the Yonsei Severance Hospital (YSH) co-
hort (Dataset S1) and was subjected to transcriptome assembly,
and lncRNA annotations using our computational pipeline (27)
(SI Appendix, Fig. S1). In total, 6,411 lncRNAs from 4,842
annotated loci and 1,924 from 1,657 unannotated loci were iden-
tified (Dataset S2). Of the total of 8,335 lncRNAs, 465 (305 up-
regulated and 160 down-regulated) were significantly dysregulated
in ESCC, exhibiting greater than 2-fold differences in expression,
with a false discovery rate (FDR) ≤ 0.01 (Fig. 1A and Dataset S3).
Then, to identify an ethnically independent set of DE lncRNAs in
ESCC, 113 DE lncRNAs commonly dysregulated in all 3 ESCC
cohorts (YSH, Genotype-Tissue Expression [GTEx] + The Can-
cer Genome Atlas [TCGA], and Chinese) were selected (Fig. 1A).
Of the 113 confidence DE lncRNAs, 20 were newly annotated, 32
were up-regulated, and 81 were down-regulated in ESCC (SI
Appendix, Fig. S2 A–C). A majority of the confidence DE lncRNA
genes were either located in intergenic regions or were antisense
to other genes (Fig. 1B); their genomic and clinical features, such
as subcellular localization of the lncRNA (Fig. 1C), associations
with enhancers (Fig. 1D), and DNA methylation (Fig. 1E), were
systematically examined (Dataset S4 A–D). As previously reported,
many overlapped with enhancers (Fig. 1D) and seemed to be
associated with epigenetic markers of other genes (Fig. 1E).
Six lncRNAs Define 4 ESCC Subclasses with Different Clinical Outcomes.
To find clinically relevant lncRNAs that are associated with survival
outcomes of patients, Kaplan–Meier survival analysis for all 113
DE lncRNAs were performed with TCGA ESCC datasets
comprising 95 patient samples (Fig. 1F and Dataset S4E). Six
DE lncRNAs were significantly associated with survival rates, 2
(HERES and RP11-1L12.3) of which were associated with a high
hazard ratio (HHR; P ≤ 0.05) and 4 (RP11-114H23.1, RP11-
114H23.2, CTD-2319I12.1, and LINC00330) of which were asso-
ciated with a low hazard ratio (LHR; P ≤ 0.05). To delineate how
the expression of the 6 lncRNAs stratifies ESCC patients, we
clustered samples from the TCGA and YSH cohorts including
additional 10 RNA-seq samples where the clinical values were
available based on the binary expression patterns (high and low)
of the 6 lncRNAs, revealing 4 distinct classes of patients: class
L1∼L4 (Fig. 1G and Dataset S5). Noticeably, class L1, in which
only the HHR markers are highly expressed, showed a worse
survival rate than class L3 (P < 0.05) and the other classes (P =
0.01; Fisher’s exact test). Class L3 tended to display a greater
overall survival rate than other classes (P < 0.05; Fisher’s exact
test). Importantly, class L1 appeared to be significantly asso-
ciated with smoking (P < 0.05; Fisher’s exact test), compared to
other classes. Taken together, these results indicate that the 6
lncRNAs represent prognostic signature genes that can stratify
ESCC patients based on clinical outcomes.
HERES Encodes Alternative Splicing Isoforms, Up-Regulated in ESCCs.
Since HERES, 1 of the HHR markers, was greatly up-regulated
in ESCCs compared to paired adjacent noncancerous samples
(SI Appendix, Fig. S3) and most strongly associated with poor
vital status (Fig. 1G), we investigated whether HERES might be
an ESCC-driving lncRNA. The lncRNA gene encodes 2 isoforms
with the same transcription start sites (TSSs) (28) and cleavage
and polyadenylation sites (CPSs) (29) (Fig. 2A). Isoform #1,
HERES.1, is 2,160 nt and contains 2 exons, whereas isoform #2,
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Fig. 2. HERES is a highly expressed lncRNA in ESCC. (A) The HERES genomic locus with CAGE-seq and 3P-seq signals. qRT-PCR primer sets were designed to
recognize exonic (2) and intronic regions (3). The coding potentials calculated by CPC and CPAT are indicated on the right. (B) qRT-PCR results using the
5 primer sets in KYSE-30 cells. (C) The HERES expression level was measured in 5 ESCC cell lines and a normal esophageal cell line (Het-1A). (B and C) Error bars
represent the mean ± SD from 3 independent experiments. (D) The box plots show the HERES expression levels in normal, noncancerous, and cancerous
tissues from the YSH cohort (paired), the Chinese cohort (paired), and the TCGA cohort. (E ) HERES expression levels measured by qRT-PCR in additional
frozen tissue samples including YSH ESCC (n = 66) and adjacent samples (noncancer; n = 66) (Left) and in normal mucosa tissues (n = 21) from reflux
symptom patients (Right). (F) Survival analyses of YSH and TCGA patients from whom the ESCC samples were obtained based on the HERES expression level.
**P ≤ 0.01, ***P ≤ 0.001.
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HERES.2, is an intron-retained, single-exonic transcript that is
6675 nt. Both isoforms were confirmed to lack coding potential
(Fig. 2A). Analysis of ESCC RNA-seq datasets (SI Appendix, Fig.
S4A) and qRT-PCR in an ESCC cell line (KYSE-30) (Fig. 2 A
and B) showed that HERES.1 is the major isoform. Only a short
region in HERES exon 1 displays sequence conservation with a
region in the mouse genome; the intergenic HERES locus be-
tween the GLS and NAB1 genes on chromosome 2 shows syn-
teny conservation in mouse (SI Appendix, Fig. S4B).
Elevated HERES expression was then validated in other
ESCC cell lines. Compared to that in a normal esophageal epithelial
cell line (Het-1A), HERES expression appeared to be up-regulated
greater than 10-fold in all tested ESCC cell lines (Fig. 2C), as ob-
served in ESCC samples (Fig. 2D). HERES was significantly up-
regulated not only in ESCC, but also in esophageal adenocarci-
noma (ESAD) and other squamous carcinomas (head and neck,
and lung squamous cell carcinoma; HNSC and LUSC), but not
in lung adenocarcinoma (LUAD) (SI Appendix, Fig. S4C). These
expression changes were further confirmed in 66 ESCC samples
from the YSH cohort using qRT-PCR, which revealed an elevated
level of HERES in cancers compared to adjacent noncancerous
samples (Fig. 2 E, Left). HERES expression in the adjacent non-
cancerous samples was higher than that in normal mucosa from the
normal population (Fig. 2 E, Right). As observed in the YSH cohort
(Fig. 2 F, Left and Dataset S6), HERES levels were significantly
correlated with stage-free survival rates in the TCGA ESCC cohort
(Fig. 2 F, Right), and multivariate analysis with clinical information
revealed that the HERES level was strongly associated with tumor
grade (P = 0.004; Fisher’s exact test) but not with other clinico-
pathological factors (SI Appendix, Fig. S4D).
HERES Promotes Cell Proliferation, Migration, Invasion, and Colony
Formation. To investigate whether HERES is involved in cancer
development and progression, the effects of HERES knockdown
on cell proliferation, migration, invasion, and colony formation were
explored with siControl- and siHERES-treated cells. Introduction
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of an siRNA targeting HERES (siHERES_1 or siHERES_2) to
KYSE-30 and HCE-7 cells significantly reduced HERES expression
(SI Appendix, Fig. S5). The proliferation indices (optical density
[O.D.] values) were significantly reduced in both siHERES_1
and siHERES_2-treated cells compared to siControl-treated
cells (Fig. 3A), and the introduction of a HERES pcDNA ex-
pression construct partly rescued the proliferation activity
(Fig. 3A), indicating that HERES can regulate cell proliferation.
Migration and invasion assays showed that both cell migration
and invasion were greatly reduced in siHERES-treated cells
compared to siControl-treated cells (Fig. 3 B and C). In addition,
HERES knockdown also reduced colony formation measured at
14 d after siRNA transfection (Fig. 3D). A role for HERES in
malignant ESCC progression was confirmed by the reduction of
N-cadherin and vimentin levels in siHERES-treated cells and by
the rescue of these levels by the introduction of the HERES
pcDNA construct to the cells (Fig. 3E and SI Appendix, Fig. S6).
These results suggest that HERES can promote cancer progression
and metastasis.
HERES Affects Wnt Signaling Pathway-Related Genes. To study the
means by which HERES promotes cancer development and pro-
gression, the changes in expression of ∼730 cancer-related pathway
genes were analyzed in siHERES-treated and siControl-treated
KYSE-30 cells using the NanoString nCounter PanCancer Path-
ways Panel (Fig. 4A and Dataset S7). Seventy-seven cancer-related
genes (34 for up-regulation and 43 for down-regulation) were
dysregulated greater than 2-fold in siHERES-treated cells
compared to siControl cells (Fig. 4A); the expression changes of
the 2 most up-regulated genes (CACNA2D3 and SFRP2) and the
2 most down-regulated genes (BMP7 and GRIN1) in this group
were confirmed by qRT-PCR (SI Appendix, Fig. S7 A–D). No-
ticeably, among the genes dysregulated by HERES reduction, 14
belong to the Wnt signaling pathway, and half of the 10 most up-
regulated genes (CACNA2D3, SFRP2, CACNA1E, CXXC4, and
SFRP4) are involved in the Wnt signaling pathway (Dataset S7).
CACNA2D3, which encodes a subunit of the calcium channel
protein complex, was previously shown to be induced in ESCC
(30) and other cancers (31, 32) via epigenetic mechanisms, and
its down-regulation led to inactivation of Wnt/Ca2+ signaling
pathway (32). SFRP2 encodes a member of the SFRP family that
modulates the Wnt signaling pathway; SFRP2 hypermethylation
is known to enhance cell invasiveness in both cancers and non-
cancerous diseases (33, 34). The enrichment of canonical and
noncanonical Wnt signaling pathway-related genes among the
genes that respond to HERES depletion, together with results
from previous studies, suggest that HERES may regulate cancer
development via control of Wnt signaling pathways.
HERES Regulates Wnt Signaling Pathways at the Epigenetic Level. As
HERES appeared to be enriched in the nucleus rather than the
cytoplasm (Fig. 4B and SI Appendix, Fig. S2C) and nucleus-
localized lncRNAs are often reported to be epigenetic regulators,
a potential epigenetic role for HERES was investigated by an-
alyzing publicly available array-based DNA methylation and
RNA-seq data from TCGA ESCC samples. Based on theirHERES
expression level, the ESCC samples were first divided into 2 sub-
groups, HERES-high and HERES-low, and the changes in expres-
sion and DNA methylation of the protein-coding genes were then
compared between the subgroups (Fig. 4C and Dataset S8). Of the
genes, CACNA2D3 and LDOC1 (Fig. 4D and SI Appendix, Fig. S7E)
were down-regulated and hypermethylated in the HERES-high
group, whereas EPSTI1, SLC15A3, and BST2 were up-regulated
and hypomethylated in the HERES-high subgroup. The expression
and DNA methylation changes were confirmed in HERES-depleted
KYSE-30 cells by qRT-PCR and methylation-specific (MS) PCR.
Only 2 down-regulated genes (CACNA2D3 and LDOC1) were
confirmed to have both expression and DNA methylation changes
(Fig. 4E and SI Appendix, Fig. S7 F–L). On the other hand, although
SFRP2 and CXXC4 did not display DNA methylation changes in the
analysis of the TCGA ESCC samples, the expression and DNA
methylation signals of the Wnt signaling-related genes were changed
similarly to those of CACNA2D3 and LDOC1 in the siHERES-
treated cells compared to the siControl-treated cells (SI Appendix,
Fig. S7B and S8 A–C).
Because DNA methylation is often associated with histone
modifications (35, 36), global changes in histone modification
markers in response to HERES knockdown were examined, re-
vealing a marked decrease in H3K27me3 levels (Fig. 4F). We then
investigated where the H3K27me3 signal was depleted in the
genomic regions of 3 Wnt signaling pathway genes in siHERES-
treated cells using chromatin immunoprecipitation (ChIP)-qPCR
analysis. Significantly reduced H3K27me3 signals were observed
at specific sites in the genes (recognized by primer 5 for CACNA2D3,
primers 3, 4, and 5 for SFRP2, and primers 9 and 10 for
CXXC4) in siHERES-depleted cells (Fig. 4G and SI Appendix,
Fig. S8 D and E).
Previous studies reported that CACNA2D3 down-regulation
inhibited the noncanonical Wnt/Ca2+ signaling pathway by de-
creasing the intracellular calcium level and NLK expression (32)
and that SFRP2 and CXXC4 play roles as negative regulators of
the canonical Wnt signaling pathway (34, 37). We thus examined
changes in the expression of 2 Wnt signaling-related factors,
NLK and β-catenin, in siHERES-treated cells (Fig. 4H and SI
Appendix, Fig. S9). As expected, HERES reduction increased the
NLK level and decreased β-catenin in KYSE-30 and HCE-7
cells. In addition, changes in the expression of Wnt downstream
targets were also confirmed (Fig. 4H and SI Appendix, Fig. S9). In
contrast, introducing the pcDNA-HERES construct to cells
reverted the expression levels of NLK, β-catenin, and Wnt
downstream targets (Fig. 4H and SI Appendix, Fig. S9). Taken
together, these results suggest that HERES down-regulation in
cancers perturbs and promotes canonical and noncanonical
Wnt signaling pathways via epigenetic regulation, resulting in
the inhibition of cancer progression.
Inhibition of HERES Arrests the Cell Cycle at the G1/S Checkpoint and
Induces Apoptosis. Because 2 of the downstream targets of
HERES, CCND1 and CACNA2D3, are known to regulate the
cell cycle and apoptosis (30, 32), the effect of the loss of HERES
on the cell cycle and apoptotic processes was examined. Cell
counting showed that siHERES-treated cells were arrested at
G0/G1 (Fig. 5A). Flow cytometry showed that siHERES-treated
cell populations exhibited significantly increased levels of apo-
ptosis compared to siControl-treated cells (Fig. 5B). An induction
of apoptotic factors, such as cleavage of poly (ADP ribose) poly-
merase (PARP), cleaved caspase-9, and Bax, and a reduction of the
anti-apoptotic factor, Bcl-2, were confirmed in siHERES-treated
cells. However, the rescue of HERES expression reverted the ex-
pression of these factors to levels in control cells (Fig. 5C).
HERES Interacts with EZH2 to Regulate CACNA2D3. We then asked
how HERES regulates the expression of target genes at the
epigenetic level. To address this question, binding sites for possible
epigenetic modulators that can drive the histone methylation of
target genes were first examined using publicly available ChIP-
seq datasets from the ENCODE project. We found that all 3
HERES target genes contained enhancer of EZH2 binding sites
in their promoter regions (SI Appendix, Fig. S10). Because EZH2,
a subunit of the PRC2, has a well-known role in histone methyl-
ation to generate H3K27me3 and is known to interact with nuclear
lncRNAs (38), we suspected that EZH2 would be a binding part-
ner of HERES. To examine the molecular relationship between
HERES and EZH2, EZH2 RNA and protein levels were quanti-
fied in siControl- and siHERES-treated KYSE-30 cells, showing
that HERES reduction decreased the EZH2 protein level but not
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the RNA level (Fig. 6A and SI Appendix, Fig. S11A). Subsequently,
RNA immunoprecipitation (RIP) (Fig. 6B) and EZH2 IP (Fig. 6C)
assays showed the interaction of HERES and CACNA2D3 with
EZH2. To validate a direct interaction between HERES and
PRC2-EZH2, we then searched for PRC2-EZH2 binding motifs
in the HERES sequence. Because the PRC2 complex including
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EZH2 is known to be recruited by G-rich motifs (39), we scanned
for G-rich regions in HERES transcripts, leading to the identification
of 6 regions including 2 potential g-quadruple structure motifs (SI
Appendix, Fig. S11B). EZH2-IP and qRT-PCR showed that a single
region with 4 GGW repeats (index 1) was significantly enriched in
EZH2-IP (SI Appendix, Fig. S11C). To further investigate if the
HERES GGW repeat sequence (index 1) is necessary for an in-
teraction with EZH2, we constructed a plasmid vector that harbors
a HERES sequence that lacks the GGW repeat region (HERES-
Mut) (Fig. 6D). A RIP assay confirmed that EZH2 failed to
interact with HERES-Mut in KYSE-30 cells (Fig. 6E). RNA
fluorescence in situ hybridization (FISH) of HERES and fluo-
rescein isothiocyanate (FITC) staining of CACNA2D3 validated
that HERES was principally localized to the nucleus and that the
GGW sequence (index 1) is necessary for the interaction with
EZH2 to down-regulate CACNA2D3 (Fig. 6F). Cells transfected
with HERES-Mut exhibited significantly increased CACNA2D3
at both the RNA and protein level, whereas HERES over-
expression (pcDNA-HERES) reduced the CACNA2D3 level
(Fig. 6 G and H).
HERES as a Candidate Therapeutic Target. To investigate whether
HERES controls tumor growth in vivo, we carried out xenograft
assays with siControl- and siHERES-treated cancer cell lines
(Fig. 7). Both the volume and weight of tumors derived from
HERES-depleted samples were significantly reduced compared
to tumors derived from control cells 4 wk after the injection (Fig.
7 A–C). We further examined changes in the expression of HERES
and its target genes, finding that the reduction of HERES was
maintained for 4 wk after siHERES injection (SI Appendix, Fig.
S12), whereas the levels of HERES targets were significantly
increased in tumor samples derived from HERES-depleted cells
compared to control cells (Fig. 7D). We also confirmed that
global H3K27me3 and EZH2 levels were decreased in HERES-
depleted tumor samples (Fig. 7D), suggesting that HERES is a
promising candidate therapeutic target that controls tumor
growth through the regulation of canonical and noncanonical
Wnt signaling pathways in vivo (Fig. 7E).
Discussion
A series of computational and experimental analyses showed
that HERES transcriptionally controls multiple target genes in
the Wnt signaling pathways at the epigenetic level by interacting
with the EZH2-PRC2 complex. Because the targets and HERES
are generally located on different chromosomes, HERES appears
to act via EZH2-PRC2 in trans rather than in cis. Intriguingly,
HERES RNA contains some repeat elements including GGW
and Alu repeats, which extensively match sequences in the up-
stream regions of the target genes including CACNA2D3 (SI
Appendix, Fig. S13). Particularly, the Alu repeats would provide
complementary base-pairing between HERES its target DNA
sequences as well as it might be related to the nuclear localiza-
tion of HERES, as previously reported (40).
Although we reported in this study that a G-rich motif in
HERES is important for binding to EZH2, it remains unclear
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which part of EZH2 interacts with HERES. A previous study
showed that the N-terminal region of EZH2 is important for
RNA binding through a G-rich motif (41). A series of deletion
mutants of human PRC2 revealed that the basic N-terminal helix
of EZH2, particularly residues 32–42 in the helix, are the most
critical for RNA binding through a G-rich motif. Given these
results, the G-rich motif embedded in HERES probably also
interacts with the basic N-terminal helix of EZH2, although such
a direct interaction needs to be verified.
Transcription factor ChIP-seq data from the ENCODE proj-
ect revealed that the first HERES exon contains some enhancer-
related transcription factor binding sites (TFBSs) for CEBPB,
EP300, and AP-1 subunits (JUN, FOS) (SI Appendix, Fig. S14),
suggesting that HERES could be regulated epigenetically by
modulation of the chromatin state at its locus. On the other
hand, the expression of HERES near enhancer-related TFBSs
raises the possibility that HERES is an enhancer RNA (eRNA)
that regulates neighboring genes in cis. However, 2 following
observations argue against this idea: first, HERES is highly
abundant and includes both a 5′ cap and 3′ polyadenylation,
unlike eRNAs, and second, the genes neighboring HERES were
only marginally affected by siHERES transfection (SI Appendix,
Fig. S15).
Although there have been reports that some lncRNAs partici-
pate in regulating the Wnt signaling pathway, their targets appear
limited (42). Our results suggest that HERES could be a master
regulator of the Wnt signaling pathway, because it controls key
components of both canonical and Ca2+-related noncanonical
pathways (Fig. 7E). Our results highlight the potential significance
of HERES in terms of targeted therapy, where it could be used to
manipulate Wnt signaling pathways and Ca2+ homeostasis.
Materials and Methods
Sample Collection and Preparation. Samples from 23 Korean ESCC patients
were used for RNA-seq; an additional 43 ESCC patients were also enrolled in
this study. Clinicopathological findings and tissues were obtained pro-
spectively (Dataset S6). Cancerous and adjacent noncancerous mucosa tissues
were collected by endoscopic biopsy from all 66 ESCC patients, regarded as
the YSH (Yonsei Severance Hospital) cohort. Additionally, normal mucosal
tissues from 21 patients with reflux symptoms, as well as ESCC cell lines, were
used in the study. Immediately after collection, tissues were transferred to
RNAlater (Ambion,) and then stored at −80 °C. Total RNA was extracted
from ESCC cells and tissues and then subjected to qRT-PCR for construction
of RNA-seq libraries (SI Appendix, Methods for more details). All tissue
samples were obtained after receiving written informed consent from pa-
tients according to the Declaration of Helsinki, and this study was approved
by Institutional Review Board (IRB) of the Yonsei University College of Medicine
(# 4–2011-0891).
Annotations and Expression Profiling of lncRNAs. To profile both annotated
and unannotated lncRNAs expressed in ESCC, transcriptome assembly and
lncRNA annotations were performed over the initial 13 RNA-seq datasets
obtained from the YSH cohort using our computational pipeline (SI Appendix,
Methods for more details). Using the resulting annotations of all lncRNAs,
lncRNA expression levels were measured over the YSH cohort, publicly avail-
able ESCC cohorts (95 tumor samples from TCGA and 15 paired samples from
a Chinese ESCC cohort) (26, 43), and GTEx Esophagus mucosa datasets (328
samples) (44) (SI Appendix, Methods for more details). Because the RNA-seq
data from the TCGA ESCC and GTEx Esophagus mucosa datasets were
unstranded types (reads with no strand information), the strand information
was predicted and the unstranded reads were converted to RPDs (reads with
predicted directions) using CAFE (27).
Methylation-Specific PCR (MS-PCR). Genomic DNA was extracted from KYSE-
30 cells using a DNeasy Blood and Tissue kit (Qiagen). An EZ DNAMethylation-
Gold kit (ZymoResearch) was used for DNA bisulfite transformation. MS-PCR
was performed using primers specific for methylated and unmethylated genes
(Dataset S9).
ChIP Assay. For chromatin shearing in lysates of cells transfected with small
interfering RNA (siRNA) (siHERES or siControl), we used waterbath sonication
for 30 cycles under cooling conditions, 15 s on, 30 s off (170–190 W). The
fragmented chromatin was extracted using a High-Sensitivity ChIP kit
(ab185913; Abcam), according to the manufacturer’s protocol. A total of
5 μg of total chromatin was used for ChIP with anti-H3K27me3 (ab6002;
Abcam) and the mock immunoprecipitation (IP) (IgG, ab185913; Abcam) at
4 °C overnight. After cross-link reversal and DNA purification, 1 μL of eluted
DNA was used for qRT-PCR with target region primers. The primer sequences
for qRT-PCR are shown in Dataset S9.
RIP Assay. To immunoprecipitate RNA-protein complexes, cells were first lysed
with nuclear isolation buffer (1.28 M sucrose, 40 mM Tris·HCl pH 7.5, 20 mM
MgCl2, 4% Triton X-100) and resuspended in RIP buffer (150 mM KCl, 25 mM
Tris·HCl pH 7.4, 5 mM EDTA, 0.5 mM DTT, 0.5% Nonidet P-40, 1 U/μL RNase
inhibitor, and protease inhibitor). To achieve chromatin shearing, waterbath
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Fig. 7. Expression of HERES regulates tumorigenicity in xenograft models. KYSE-30 cells transfected with either siControl or siHERES were injected into nude
mice (6 mice for each group). The resulting xenograft tumor volumes (A and B) and weights (C) are shown. (A) Tumor growth curves showing that tumors in
the siHERES group grew markedly slower than those in the siControl group. (B) Images of tumor volumes from the xenograft models. (C) Tumor weights in
the siHERES and siControl groups 4 wk after cell injection. Data represent the mean ± SD. (D) Immunoblot analysis (#1 and #2) of levels of key components
(CACNA2D3, SFRP2, and CXXC4) from the canonical and noncanonical Wnt signaling pathways and of H3K27me3 and EZH2 in the siHERES and siControl
xenograft models. (E) A graphic illustration of HERES-regulated canonical and noncanonical Wnt signaling pathways in ESCC. *P ≤ 0.05.
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sonication was administered for 30 cycles and the lysate was cleared by
centrifugation. The appropriate antibody (2 μg) was added to the resulting
supernatant (600–800 μg) and the mixture was carefully incubated at 4 °C for
24 h or more on a rotator. After incubation, 20 μL of Magna Chip protein
magnetic beads (Merck Millipore) were added, and the solution rotated at
4 °C for 2 h. After washing with RIP buffer, qRT-PCR and Western blotting
were carried out following RNA purification with TRIzol reagent or SDS gel
electrophoresis, respectively.
Mutagenesis Assay.Mutagenesis of the PRC2-EZH2 binding site in HERES was
conductedusingaQ5Site-DirectedMutagenesis kit. HERES_NheI_F acccaagctggctagc
GGCAACCAGCTTGCGTCC and HERES_XbaI_r aaacgggccctctaga TTTAAATGA-
TAGGGTATTGG were used as the cloning primers to insert the wild-type (WT)
HERES cDNA into pcDNA3.1.
HERES-Mut_AS:
TATTTACCTGAATATGTCTTGTATTCATTCATGTAAATTA and
HERES-Mut_S: TAATTTACATGAATGAATA C AAGACATATTCAGGTAAATA
primers were used to create HERES-Mut. HERES-Wt and HERES-Mut se-
quences were confirmed by Sanger sequencing.
Xenograft Assay in NudeMice.All animal experiments were performed using a
protocol approved by Institutional Animal Care and Use Committee at the
Catholic University, College of Medicine (2018-0619-01). After transfection
of siControl or siHERES, 2 × 106 KYSE-30 cells were suspended in 200 μL of
Matrigel solution (BD Biosciences) and s.c. implanted onto the posterior
flank of BALB/c nude mice (6-wk-old male, n = 6). The volume of the
resulting cell mass after 4 wk was measured using a vernier caliper and the
mass of each xenograft tumor was analyzed after the animal was euthanized
according to the Guide for the Care and Use of Laboratory Animals (45).
Data Availability. Raw RNA-seq data and expression tables from ESCC patients
have been submitted to the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE130078. LncRNA annotation constructed in this
study can be downloaded from our website (http://big.hanyang.ac.kr/CASOL/
catalog.html).
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